- Home
- NUVL vs DY Comparison
NUVL vs DY Comparison
Compare NUVL & DY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NUVL
- DY
- Stock Information
- Founded
- NUVL 2017
- DY 1969
- Country
- NUVL United States
- DY United States
- Employees
- NUVL N/A
- DY N/A
- Industry
- NUVL Biotechnology: Pharmaceutical Preparations
- DY Water Sewer Pipeline Comm & Power Line Construction
- Sector
- NUVL Health Care
- DY Industrials
- Exchange
- NUVL Nasdaq
- DY Nasdaq
- Market Cap
- NUVL 5.5B
- DY 5.1B
- IPO Year
- NUVL 2021
- DY N/A
- Fundamental
- Price
- NUVL $79.49
- DY $171.73
- Analyst Decision
- NUVL Strong Buy
- DY Strong Buy
- Analyst Count
- NUVL 11
- DY 8
- Target Price
- NUVL $112.36
- DY $208.88
- AVG Volume (30 Days)
- NUVL 420.4K
- DY 426.3K
- Earning Date
- NUVL 03-04-2025
- DY 02-26-2025
- Dividend Yield
- NUVL N/A
- DY N/A
- EPS Growth
- NUVL N/A
- DY 2.58
- EPS
- NUVL N/A
- DY 7.59
- Revenue
- NUVL N/A
- DY $4,569,944,000.00
- Revenue This Year
- NUVL N/A
- DY $14.52
- Revenue Next Year
- NUVL N/A
- DY $13.28
- P/E Ratio
- NUVL N/A
- DY $22.59
- Revenue Growth
- NUVL N/A
- DY 10.37
- 52 Week Low
- NUVL $61.80
- DY $118.00
- 52 Week High
- NUVL $113.51
- DY $207.20
- Technical
- Relative Strength Index (RSI)
- NUVL 43.83
- DY 38.28
- Support Level
- NUVL $77.84
- DY $169.74
- Resistance Level
- NUVL $85.21
- DY $182.45
- Average True Range (ATR)
- NUVL 3.78
- DY 7.65
- MACD
- NUVL -0.46
- DY -2.63
- Stochastic Oscillator
- NUVL 12.08
- DY 13.06
About NUVL Nuvalent Inc.
Nuvalent Inc is a clinical stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically proven kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.
About DY Dycom Industries Inc.
Dycom Industries Inc is a provider of specialty contracting services to the telecommunications infrastructure and utility industries. its operating companies supply telecommunications providers with a comprehensive portfolio of specialty services, including program management; planning; engineering and design; aerial, underground, and wireless construction; maintenance; and fulfillment services and provides underground facility locating services for various utilities, including telecommunications providers, and other construction and maintenance services for electric and gas utilities. It also provides a range of construction, maintenance, and installation services, including the placement and splicing of fiber, copper, and coaxial cables. The company operates throughout the United States.